Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
about
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cellsMolecular biology of lung cancer: clinical implicationsMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersGefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutationMolecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerRecent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsTargeting RTK Signaling Pathways in CancerMolecular testing in lung cancer in the era of precision medicineEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerRole of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patientsAdditional Serine/Threonine Phosphorylation Reduces Binding Affinity but Preserves Interface Topography of Substrate Proteins to the c-Cbl TKB DomainMolecular pathology of lung cancer: key to personalized medicine.Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.Neuraminidase-1: a novel therapeutic target in multistage tumorigenesisCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceNeonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunctionModeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expressionAlternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancerContribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma TreatmentsMechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerFocal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerThe Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor.Pathway-driven discovery of rare mutational impact on cancerDetection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices.The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity.EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practiceThe energy landscape analysis of cancer mutations in protein kinasesAPOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data.Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA deliveryA phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Molecular pathways and therapeutic targets in lung cancerCorrelation between (18)f-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in advanced lung cancerExpanding the utility of beta-galactosidase complementation: piece by piece.Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapySOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
P2860
Q24305557-41245A9D-3EEF-4680-A2E6-CD7DB4908923Q24610335-5F200B74-FE34-4927-81E4-2800F254911AQ24611043-90610DA5-5050-467D-BB22-AD31C7CD9E71Q26739096-755F5DD8-E3F7-4C75-9AD3-55A4CC8A3981Q26771116-2DB23B26-FA50-45ED-8968-FAECC223D5D5Q26774478-48CE25E8-71FB-4670-B2DA-8B309989D1B1Q26774625-CE4A24F4-C4C9-4A22-AA35-03DAA0C05E61Q26781278-2405288C-BEDA-4B11-8F5E-5B69412E62F1Q26824599-AB6993E8-5D88-4465-8273-29213E781FFCQ26852507-19EE5368-D92E-4EFC-AC27-80CF0FCA2781Q26866485-732150F9-51A5-413E-B45B-E5D9F776BA5BQ27664726-424160CD-C2FF-407C-805C-5F4C33BDC18FQ27691299-0E615DD4-A470-40E3-8704-49D9A94679BAQ27691330-66A2B5BC-B1D7-4D2D-9C5B-8E6E3EF21B9AQ27852932-CC3B71A3-794E-42E5-8B27-270224489E8FQ28066130-85CFC19A-6176-45D3-8946-E9E2C9116BB8Q28077340-77FA9270-F548-4C35-80D0-6808BD252F07Q28079320-B656A2A6-1999-4DA8-9F62-2D8FC62CA187Q28477465-E4AC4C18-4CB9-4AFC-ACDC-3D71BE85FC41Q28484612-78304B70-2E48-4C94-BC09-493B6E2FE94DQ28534819-BBA1E879-5519-43F2-8B9C-E4DF99C11B08Q28547357-068E2957-9A5C-480C-876B-40CF4720B40BQ28547446-B7E85005-3D43-4EA6-83EE-C27ECCAE2E2CQ28550689-D6C5E49A-D083-4248-83E4-51E202C5A5A1Q30009944-EE3270D5-F38D-40C9-9A34-31A85563EA9DQ30363088-76230138-60EA-4E00-ABA0-31DA8AFD5D4DQ30365308-47E39897-9237-468A-AE0E-1BB931FE624EQ30433023-25EE04B9-414A-4E4C-8034-203EAFB176A1Q30498197-2EE011B4-6BF0-4DEB-958B-44044A9E666AQ30664830-29C07348-65A0-43D0-83ED-5274DFBA9AF0Q31038185-B3D94415-C244-4F43-8C23-6C857F691025Q31133537-13B00225-AEBF-427C-AA22-C6339D8118F4Q33587012-92B9E003-E3FA-43D8-9AC5-F7408B0D29B6Q33599860-82B27DE2-DC44-4D5A-8216-B42A50049F07Q33605906-2B134A93-C23D-4358-B8BD-C9FCDDAFE79EQ33688872-FB6611C6-49BE-44AB-8D7F-B7DABD822121Q33704537-09196293-3E4F-409C-9C48-5035AF1F4E8EQ33715334-54F9CF4D-251B-4F86-BD6F-393A1CCEFE93Q33757134-FB63F91C-E255-4BC3-B76D-A96434F3030EQ33757287-276FA00E-5841-491C-83AF-FB606407F671
P2860
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@ast
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@en
type
label
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@ast
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@en
prefLabel
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@ast
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@en
P2860
P356
P1433
P1476
Activating and resistance muta ...... GFR tyrosine kinase inhibitors
@en
P2093
A F Gazdar
P2860
P2888
P304
P356
10.1038/ONC.2009.198
P407
P478
28 Suppl 1
P577
2009-08-01T00:00:00Z
P5875
P6179
1030987778